STRO Stock Forecast & Price Target

Sutro Biopharma is positioned favorably because STRO-004 is showing early clinical validation in a TF-targeted setting where Tivdak is currently the only FDA-approved ADC, and the asset’s DAR8 exatecan design plus Fc-silent backbone appears to offer a more differentiated therapeutic window with less systemic exposure than first-generation TF ADCs. The July 24, 2026 cutoff data showed 49 patients treated, rapid enrollment within seven months, manageable safety in the clinically relevant 3–5 mg/kg range, limited free exatecan exposure, no neuropathy or ILD/pneumonitis signal, and emerging confirmed and unconfirmed partial responses across PDAC, HNSCC, and NSCLC, while the company still had $164.3MM in cash, cash equivalents, and marketable securities expected to fund operations into at least 2Q28. In addition, the pipeline has multiple upcoming catalysts, including STRO-006 entering Phase 1 in 3Q26, STRO-227 IND submission in 2026, and other programs expected by YE26 and by 2027, which supports a broader platform-driven growth story with meaningful optionality beyond STRO-004.

Sutro Biopharma is viewed negatively because its valuation is still heavily dependent on early-stage, high-risk clinical assets whose lead program STRO-004 is only in a Phase 1 STRIVE study with open-label dose escalation and expansion parts, meaning meaningful efficacy and tolerability data remain unproven. The company’s own risk disclosure highlights that the biggest near-term threat is poorer-than-expected clinical results from its lead ADC candidates, which could force lower penetration assumptions, higher discount rates, and longer or failed approval timelines, while longer-term value is also exposed to partnered and wholly owned preclinical programs and competitive and reimbursement pressure. Although it had $160.8MM in cash at the end of 2Q27 and 25.8MM shares outstanding, that balance does not eliminate the fundamental uncertainty around achieving the cited ORR, DCR, DOR, PFS, and 12-month survival targets, nor does it offset the reliance on distant 2033/34 and 2034 sales assumptions to support valuation.